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Key Points




IBR 420 mg daily in
combination with VEN
200 mg daily were
identiﬁed as having
the highest response
and lowest toxicty in
relapsed MCL.
Additional beneﬁt was
not seen at higher
doses. Resistance
was seen at all dosing
combinations, suggesting a biologic
resistance
mechanism.

Relapsed Mantle cell lymphoma (MCL) is often treated with Bruton’s tyrosine kinase
inhibitors (BTKi); however, post-BTKi relapse can be challenging. Adding venetoclax
(VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models. Prior MCL studies
of the combination show promising efﬁcacy but have conducted limited dose ﬁnding. We
sought to identify the optimal dosing combination, based on efﬁcacy and toxicity,
utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and
560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily).
Eligible participants were not previously exposed to BTKi and not high risk for tumor
lysis syndrome (TLS). VEN, initiated ﬁrst at 100 mg, then at 20 mg by mouth daily after a
TLS event, was started prior to adding IBR and ramped-up based on the dose level
assigned. Combination treatment continued for six 28-day cycles. Thirty-ﬁve participants
were enrolled and treated. One TLS event occurred with starting dose of 100 mg VEN; no
TLS was seen with 20 mg. The optimal dosing combination was considered to be VEN
200 mg and IBR 420 mg with an overall response rate (ORR) of 93.8% (95% CI: 73.6% to
99.7%) and DLT incidence of 6.2% (95% CI: 0.3% to 26.4%). ORR for all arms was 82.3%
(28/34; 95% CI: 65.5% to 93.2%) with a complete response (CR) rate of 42.4% (14/33; 95%
CI: 25.5% to 60.8%). A participant was not allocated to IBR 560 mg and VEN 400 mg. ORR
beneﬁt was not seen with higher dosing combinations and toxicity was higher; a
comparison made within the limitations of small cohorts. Resistance was seen in nearly
all arms. This trial was registered at www.clinicaltrials.gov #NCT02419560.

Introduction
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin lymphoma (NHL) with an incidence of around
4000 to 5000 cases per year1-3 in the United States. There are multiple histologic and clinical phenotypes ranging from an indolent, non-nodal subtype4-7 to an aggressive blastoid variety.2 MCL is typically
treated with immunochemotherapy followed by high-dose chemotherapy with autologous stem cell rescue in transplant-eligible patients.8-12 However, despite aggressive therapy, a cure is seldom attained,
with progression-free survival (PFS) ranging from a median of 7 to 9 years, depending on the induction
treatment approach.8-11
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BCL-2 is an antiapoptotic protein that is dysregulated in many
B-cell malignancies, including MCL.24 VEN is a small molecule, oral
BCL-2 inhibitor with a high afﬁnity to BCL-2 over other antiapoptotic
proteins.25 Early studies with VEN showed rapid tumor cell killing
complicated by tumor lysis syndrome (TLS), particularly in patients
with CLL, necessitating a dose ramp-up to mitigate TLS.26 VEN has
activity as a single agent in MCL with a response rate of 75% in a
phase 1 study.27 However, despite early response, responses were
not long-lasting27. VEN had activity at maximum dose ranges from
400 mg to 800 mg by mouth daily.
To date, IBR and VEN have been combined in 2 published MCL
studies. AIM used the single-agent phase 2 dose of each drug (IBR
560 mg by mouth daily and VEN 400 mg by mouth daily) in 24
patients with relapsed/refractory disease.28 OAsIs combined obinutuzumab with IBR plus VEN in a staged, phase 1/2 manner. IBR
was ﬁxed at 560 mg by mouth daily, and VEN was given at 400
mg, 600 mg, and 800 mg daily in a dose-escalation strategy.29
However, as patients treated at higher doses experienced more
transfusion support and, as the preclinical rationale showed no
improvement in efﬁcacy at doses higher than 400 mg, 400 mg by
mouth daily was used as the phase 2 dose. Importantly, hematologic toxicity was common in relapsed or refractory patients, primarily thrombocytopenia and neutropenia. Both studies treated patients
with IBR for 4 weeks prior to starting the VEN dose ramp-up.
Given the preclinical rationale for the combination of IBR and
VEN as well as concerns for toxicity, as both drugs are metabolized via CYP3A, we employed a dose-ﬁnding study in relapsed
and refractory MCL to identify the optimal combination (ClinicalTrials.gov identiﬁer NCT02419560). VEN was initiated ﬁrst, and
IBR was added during the VEN dose ramp-up; thus achieving the
planned maximum dose earlier in the treatment course. We
hypothesized that doses lower than the single-agent dose could
achieve similar efﬁcacy with limited toxicity. A continual reassessment method (CRM) was used to identify the optimal dose combination, deﬁned as the combination of doses, which resulted in a
dose-limiting toxicity (DLT) rate #25% and maximized the ORR
(complete 1 partial remission) at 2 months posttreatment.

Methods
Patients
Eligible patients were $18 years of age, diagnosed with MCL
(deﬁned as the presence of cyclin D1 expression and/or t(11;14)
8 MARCH 2022 • VOLUME 6, NUMBER 5

by ﬂuorescence in-situ hybridization [FISH]) and relapsed after 1 or
more chemotherapy-containing regimens. Prior treatment with a
BTKi was not allowed. Potential participants must have had radiographically measurable disease deﬁned as at least 1 lymph node
(LN) $2 cm in longest diameter or splenomegaly .13 cm in craniocaudal dimension. Participants at high risk for tumor lysis, deﬁned
as having active TLS, a measurable LN $10 cm, or a LN $5cm
and an ALC (absolute lymphocyte count) .25 3 109/L, were
excluded. Adequate organ function, including a calculated or measured creatinine clearance of $50 mL/min, was required. Potential
participants who required treatment with CYP3A inhibitors or potent
inducers or required warfarin for anticoagulation were excluded. Full
eligibility criteria can be found in the supplemental Methods.

Treatment
A CRM was used to identify the optimal dose combination of IBR
and VEN among 6 different dosing combinations. IBR was tested at
3 dosing levels (280 mg, 420 mg, and 560 mg by mouth daily),
and VEN was tested at 2 dosing levels (max dose of 200 mg by
mouth daily and max dose of 400 mg by mouth daily) (Table 1). The
dosing schema is shown in Figure 1. Participants were initially
treated with 100 mg of VEN daily for 1 week before starting IBR at
the allocated dose. However, a clinically signiﬁcant TLS event
occurred (acute kidney injury with grade 4 hyperkalemia, hyperphosphatemia, and hyperuricemia occurring within 24 hours of the ﬁrst
dose of VEN 100 mg) in 1 of the ﬁrst 15 patients treated, as previously reported.30 This event necessitated a pause in enrollment and
a change to the initial dosing of venetoclax to mitigate TLS. After
study amendment, patients were treated with VEN daily dosing of
20 mg for 2 days, 50 mg for 5 days, and 100 mg for 7 days (dosing windows were allowed) before starting the allocated dose of
IBR. IBR plus 100 mg of VEN was continued for 1 week before further escalating VEN to the maximum allocated dose as per
Figure 1. TLS was closely monitored during the VEN dose rampup. The combination of IBR and VEN continued for six 28-day
cycles. Treatment after completing combination therapy was per
treating physician discretion, though the protocol did suggest continuing single-agent IBR at 560 mg by mouth daily unless otherwise
contraindicated. VEN was not provided by the study beyond cycle
6. Participants were followed for progression and survival.

Study design, dose allocation, and statistical
considerations
Details regarding the modeling approach and design considerations
have been provided in a prior report.31 Brieﬂy, participant enrollment
to the study occurred in 2 allocation phases. In the ﬁrst phase, each
participant was sequentially allocated to 1 of 4 escalating zones
comprising 6 dosing arms (Table 1). Once the DLT period elapsed
without observance of a DLT in the ﬁrst participant within each arm
of a zone, subsequent participants would be allocated to the next
increasing zone. Multiple participants could be enrolled in a given
zone if the DLT observation period had not cleared. The second
phase would begin if a DLT occurred at any time or at least 1 participant was enrolled in all arms and the DLT observation window had
been cleared.
In the second allocation phase, eligible participants were allocated
to a treatment arm based on the ORR at 2 months postcombination
treatment start and DLT incidence in previously treated participants.
Enrollment continued until 10 participants were allocated to an arm
DOSE FINDING OF IBRUTINIB AND VENETOCLAX IN MCL
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Ibrutinib (IBR), a covalent, oral, small-molecule Bruton tyrosine kinase
inhibitor (BTKi), has changed the landscape of MCL patients who
relapse after immunochemotherapy. Treatment at a dose of 560 mg
daily showed an overall response rate (ORR) of 67% and a 2-year
PFS of 31%.13,14 At this dose, there is nearly 100% BTK occupancy.15 However, not all patients with relapsed or refractory MCL
beneﬁt, with 20% to 33% of patients failing to respond to singleagent therapy,13,14,16 and complete response (CR) only occurs in
about a quarter of those treated. Relapse after IBR failure has a poor
outcome.17,18 Mechanisms of resistance to IBR in MCL remain elusive
and appear to differ19 from the BTK and Phospholipase C-Ç (PLCÇ)
mutations observed in chronic lymphocytic leukemia (CLL) treatment
failures.20,21 To study ways to improve response to IBR, our group
and others identiﬁed a synergistic combination of IBR and venetoclax
(VEN) in preclinical models that informed the present study.22,23

Table 1. Dosing allocation and outcomes
IBR (week 11) mg per day

All subjects
20-100 VEN (cycle 0)
VEN
(mg per day)

560

Zone 2/arm C (n 5 8)
ORR 6/8
CR 4/8
PD on Rx 2/8
DLT 0/8
Dose Mods†: 8/8

280

Zone 3/arm E (n 5 5)
(1 not evaluable)
ORR 3/4
CR 2/4
PD on Rx 2/4
DLT 2/5
Dose Mods†: 2/5

Zone 4/arm F (n 5 0)

200 (week 31)
200 (week 2)
100 (week 1)

Zone 1/arm A (n 5 2)
ORR 2/2
CR 1/2
PD on Rx 0/2
DLT 0/2
Dose Mods†: 2/2

Zone 2/arm B (n 5 16)
ORR 15/16
CR 6/15*
PD on Rx 2/16
DLT 1/16
Dose Mods†: 6/16

Zone 3/arm D (n 5 4)
ORR 2/4
CR 1/4
PD on Rx 2/4
DLT 0/4
Dose Mods†: 3/4

*One subject had a response but could not be evaluated for CR status.
†Dose modiﬁcations or holds.

or the maximum enrollment was reached (23 patients). The optimal
dose was deﬁned as the arm with 10 participants assigned or that
had an observed DLT rate #25% and maximized the ORR at 2
months.

previously.31 PFS and OS were estimated by the Kaplan-Meier
method.

Due to the potential safety and efﬁcacy implications of the change
in dosing strategy after study amendment related to the TLS event,
enrollment was expanded and continued until 10 patients were allocated to the modiﬁed treatment arm or a total maximum study enrollment of 38 participants. The optimal dose was similarly deﬁned but
limited to those participants enrolled after the amendment. DLT and
efﬁcacy information was used from participants treated before the
amendment to guide the starting arm for assignment after the
amendment.

All participants who received any protocol treatment were monitored
for adverse events (AEs), which were recorded based on CTCAE
v4.03. DLTs were deﬁned as AEs that were treatment-emergent
and occurring during the beginning of VEN and IBR combination
until day 28 of cycle 2 (56 days total). They included any grade $3
nonhematologic AE, febrile neutropenia of any duration, grade 4
thrombocytopenia or grade 3 thrombocytopenia with bleeding,
grade 4 anemia, or any other AE that is thought to cause substantial
morbidity for participants. Response was deﬁned via Cheson et al32
and was evaluated by computer tomography (CT) every other cycle
and positron emission tomography (PET)/CT at the end of treatment. For a response to be considered a CR, CT-based imaging

For the combination to be deemed promising, an observed ORR of
at least 60% in 10 participants treated at the optimal dose combination by a 2-month disease assessment was needed as described

Safety and efﬁcacy assessments

400 mg
Arms
C, E, F

200 mg
100 mg 100 mg
Venetoclax
Ibrutinib
dosing per
assignment

20 mg

200 mg
Arms
A, B, D

50 mg

Additional
treatment off
protocol

Week 1

Week 2 Week 1 Week 2

Cycle 0*

Cycle 1

Week 3 cycle 1 to
cycle 6 day 28

Figure 1. Treatment schema. Participants were initially treated with VEN, starting at 20 mg by mouth daily and increasing to 50 mg by mouth daily and 100 mg by mouth
daily over 2 weeks (cycle 0*). Participants must have had at least 2 but no more than 4 days of 20 mg, and 3 but no more than 5 days of 50 mg before moving to 100 mg
by mouth daily for 7 days. Ibrutinib (IBR), at the allocated dose, was added to venetoclax (VEN) at 100 mg by mouth daily for an additional 7 days (cycle 1, week 1). Weekly
VEN dose titration was continued to the allocated dose as shown.
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420

400 (week 31)
200 (week 2)
100 (week 1)

Table 2. Patient characteristics at enrollment

Characteristic

Total (%)
(n 5 35)

A
IBR 280
VEN 200
(n 5 2)

Mean age in years (min-max)

63 (49-82)

75 (69-82)

% male

29 (83%)

2 (100%)

Prior auto transplant (yes),
%

15 (43%)

0 (0%)

Refractory to last line of
therapy (yes), %

18 (51%)

2 (100%)

5 (31%)

4 (50%)

3 (75%)

4 (80%)

B
IBR 420
VEN 200
(n 5 16)

C
IBR 280
VEN 400
(n 5 8)

D
IBR 560
VEN 200
(n 5 4)

E
IBR 420
VEN 400
(n 5 5)

62 (54-76)

66 (49-79)

62 (53-68)

56 (50-60)

14 (87%)

6 (75%)

3 (75%)

4 (80%)

4 (50%)

1 (25%)

2 (40%)

8 (50%)

Lines of prior Rx
20 (57%)

1 (50%)

12 (75%)

3 (38%)

3 (75%)

1 (20%)

13 (37%)

1 (50%)

4 (25%)

3 (38%)

1 (25%)

4 (80%)

3 lines

2 (6%)

0 (0%)

0 (0%)

2 (25%)

0 (0%)

0 (0%)

Stage at enrollment
1-2

2 (6%)

0 (0%)

1 (6%)

0 (0%)

1 (25%)

0 (0%)

3

6 (17%)

1 (50%)

2 (13%)

1 (13%)

1 (25%)

1 (20%)

4

27 (77%)

1 (50%)

13 (81%)

7 (88%)

2 (50%)

4 (80%)

Low

17 (49%)

1 (50%)

9 (56%)

2 (25%)

2 (50%)

3 (60%)

Intermediate

12 (34%)

1 (50%)

5 (31%)

2 (25%)

2 (50%)

2 (40%)

6 (17%)

0 (0%)

2 (13%)

4 (50%)

0 (0%)

0 (0%)

MIPI at enrollment

High

had to be conﬁrmed with a negative PET/CT and negative bone
marrow (BM) biopsy if BM was involved at enrollment.

Trial conduct
The study was conducted at the University of Virginia in Charlottesville, VA, Washington University in St. Louis, MO, City of Hope in
Duarte, CA, and Emory University in Atlanta, GA. Each institution’s
institutional review board (IRB) approved the protocol, and the study
was conducted according to general best practices and with adherence to the Declaration of Helsinki. All participants provided written
informed consent. It was monitored and organized through the University of Virginia Clinical Trials Ofﬁce and was governed by the
FDA through IND number 124831 (CAP holder). Data cutoff was
12 October 2020.

Results
Patient characteristics
A total of 45 patients consented to the study from August 2015 to
May 2019. Thirty-seven participants were deemed eligible (reasons
for ineligibility included decreased renal function, prolonged QTc,
and absence of measurable disease). Thirty-ﬁve participants were
ultimately treated. A total of 17 eligible participants were enrolled
before the dosing change prompted by the TLS event, and 20 eligible participants were treated post change. Two eligible participants
were allocated to an arm at the time of the TLS event but had not
started treatment and were removed from protocol due to study
suspension for safety. Baseline characteristics are listed in Table 2,
and baseline characteristics pre and postamendment are in supplement table 2.
8 MARCH 2022 • VOLUME 6, NUMBER 5

Optimal dose ﬁnding
A total of 7 participants were enrolled in the ﬁrst allocation phase of
the study when a DLT of prolonged grade 4 neutropenia occurred
in arm E (VEN 400, IBR 420), prompting the initiation of the second
phase. As a result, arm F (VEN 400, IBR 560) was not tested in the
study's initial phase. An additional 10 participants were allocated via
CRM before the TLS event (2 participants were allocated but not
treated). Based on the prior 15 participants who received study
therapy prior to the amendment, arm C (VEN 400, IBR 280) was
considered a starting point after the amendment. After the amendment, allocation via CRM continued until 10 participants were allocated to arm B (VEN 200, IBR 420) and had DLT and response
information available. While DLT and ORR information was maturing, 3 additional eligible participants were allocated for a total of 13
participants in arm B and an overall total of 20 participants treated
after the amendment. The CRM did not recommend a participant
be allocated to arm F (VEN 400, IBR 560). Arm B (VEN 200, IBR
420) was considered the optimal dose combination with an ORR of
15/16 (93.8%; 95% CI: 73.6% to 99.7%) and DLT incidence of
1/16 (6.2%; 95% CI: 0.3% to 26.4%). The trial conduct of the
CRM allocation is represented in supplement table 3.

Treatment duration, toxicity, and response
Of the 35 participants allocated to and treated in an arm, 25
(71.4%) completed the 6 cycles of the combination treatment, 7
(17.1%) had disease progression or relapse before ﬁnishing therapy, and 3 (8.6%) had an AE causing treatment discontinuation. All
participants were able to transition from cycle 0 (VEN only) to cycle
1 (IBR and VEN). Common AEs are summarized in Table 3. There
were 3 DLTs consisting of persistent grade 4 neutropenia (arm E),
persistent grade 3 diarrhea (arm E), and grade 3 respiratory disorder (arm B). Dose modiﬁcations on the study were allowed and are
DOSE FINDING OF IBRUTINIB AND VENETOCLAX IN MCL
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2 lines

B

PFS all participants

Progression-free survival (proportion)

Progression-free survival (proportion)

A
1.00
0.75
0.50
0.25
0.00
0

10

20

30

40

PFS Arm B (IBR 420, VEN 200)
1.00
0.75
0.50
0.25
0.00
0

Number at risk
35

19

C

13

6

20

30

40

Time from cycle 1, day 1 (months)
Number at risk
16

3

D

OS all participants

9

7

3

1

OS Arm B (IBR 420, VEN 200)
1.00

Overall survival (proportion)

1.00

Overall survival (proportion)

10

0.75
0.50
0.25
0.00

0.75
0.50
0.25
0.00

0

10

20

30

40

0

10

Time from cycle 1, day 1 (months)
Number at risk
35

27

18

7

20

30

40

Time from cycle 1, day 1 (months)
4

Number at risk
16

13

8

4

2

Figure 2. PFS and OS. (A) PFS for all participants. (B) PFS for the optimal dose, arm B (IBR 420 mg daily and VEN 200 mg daily). (C) OS for all participants. (D) OS for
the optimal dose, arm B (IBR 420 mg daily and VEN 200 mg daily).

summarized in supplement table 4. As previously reported, the participant with the TLS event was able to continue study treatment and ﬁnished all 6 cycles of therapy.30 No other TLS events occurred.
Responses per arm are summarized in Table 1. One participant discontinued study treatment due to AE before disease assessment
and was not evaluable for response; another participant had missing
data at the end of treatment and was not evaluable for a complete
response. Overall response for all arms was 82.3% (28/34; 95%
CI: 65.5% to 93.2%) with a CR rate of 42.4% (14/33; 95% CI:
25.5% to 60.8%). Eight participants (23.5%) progressed during
therapy; 3 of these had previously had a partial response. Notably,
no demonstrable difference in response or progression was noted
between the arms.
For the 25 participants who ﬁnished the study treatment after 6
months, 14 (56%) continued to take IBR (9 at a dose of 560 mg
by mouth daily and 5 at lower doses), and 11 (44%) had other therapies (8 unknown and 3 chemotherapy).

PFS and OS
PFS and OS were estimated from cycle 1, day 1 (not including
cycle 0; there were no PFS or OS events in cycle 0). The median
follow-up for all alive patients was 26.7 months (5.5 months to 53.4
months). Median PFS and OS for the entire cohort were estimated
1494

PORTELL et al

to be 10.7 and 28.3 months, respectively. Median PFS and OS for
arm B, the optimal dose combination, were not reached with a
median follow-up of 22.9 months (5.6 months to 53.4 months)
(Figure 2). Survival should be interpreted with caution given the
study treatment only lasted for 6 cycles. In those who ﬁnished 6
cycles of combination therapy, there was an improvement in PFS
for those that continued IBR over other treatments; however,
the limited numbers did not reach statistical signiﬁcance (P 5 .10)
(Figure 3). Individual patient outcomes are summarized in a swimmer plot in supplemental Figure 1.

Discussion
We present the only known phase 1 dose-ﬁnding study of IBR and
VEN in NHL that evaluates the dosing of both drugs. Prior clinical
studies28,29 of the IBR and VEN combination have used the singleagent approved doses in combination as phase 2 studies or have
attempted to increase the approved doses in the phase 1 study.
Our approach was novel in ﬁnding the optimal dose instead of the
maximum tolerated dose, utilizing a CRM to allocate participants
based on prior participants’ efﬁcacy and toxicity. Our primary ﬁnding
shows that the optimal dose was arm B (IBR 420 mg by mouth
daily, VEN 200 mg by mouth daily), which is lower than other studies are using (SYMPATICO study, NCT03112174)33,34 or have
used (AIM or OAsIs study)28,29,35 in relapsed MCL. The
8 MARCH 2022 • VOLUME 6, NUMBER 5

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/6/5/1490/1876688/advancesadv2021005357.pdf by guest on 11 May 2022
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Time from cycle 1, day 1 (months)
Figure 3. PFS in those ﬁnishing study therapy. PFS starts at the end of therapy and compares those that were treated with IBR (red) to those that were not (blue).

SYMPATICO,33,34 AIM,28,35 and OAsIs29 studies use IBR 560 mg
by mouth daily and VEN 400 mg by mouth daily in MCL, a dose
combination that we were not able to test due to DLTs and
adequate response at lower dose levels. The reports of these studies33-35 have reported frequent dose reductions in upwards of 60%
of patients. The OAsIs study had a dose-ﬁnding portion of the study
(evaluating higher doses of VEN) with limited DLTs; however, our
deﬁnition of DLTs was conservative, and our DLT interval was long
(8 weeks). Thus, the deﬁnition of DLT between the 2 studies is different, the current study being more cautious and accounting for
the difference in DLT incidence. Toxicity has been reported with
VEN doses higher than 400 mg when combined with IBR, including
frequent hematologic toxicities.29,36 Given these overall ﬁndings,
there is comfort that dose reductions of the combination on these
studies can be effective and safe.
The ORR of 83% and a CR rate of 42% (ORR of 93.7% and a CR
rate of 40% for the optimal arm B) compares favorably to singleagent IBR ORR of 66% and CR rate 20%16 and is comparable to
the ORR of 67% in the AIM study28 and 70% in the OAsIs study
(relapsed, combination cohort only).29 There does appear to be an
improvement in CR rate in the prior studies, likely related to prolonged therapy on these studies, the use of obinutuzumab in the
OAsIs study, and our strict deﬁnition of CR rate (PET negative and
BM negative) by Lugano classiﬁcation.32 Thus, the combination is
worthy of further study, as is currently underway in the SYMPATICO
phase 3 study of IBR1VEN vs IBR1placebo in MCL
(NCT03112174). Duration of response and survival are difﬁcult to
compare as our study only provided the combination for six 28-day
cycles, and subsequent therapies were left to investigator discretion.
This also makes the achievement of minimal residual disease negative status, which we were not able to perform, difﬁcult to interpret.
The attribution of subsequent therapies to prolonged outcomes is
uncertain, though there was a trend for improvements for those who
continued IBR monotherapy.
8 MARCH 2022 • VOLUME 6, NUMBER 5

There are limitations to our study. The ﬁrst would be that our clinical
parameters at entry would portend for a more favorable MCL outcome (Table 2). This limitation is likely due to excluding participants
deemed to be at high risk for TLS and prior BTKi exposure. The latter was signiﬁcant at a time of enrollment where BTKi was mainly
used in the second-line setting, thus prioritizing enrollment to those
who had relapsed after initial treatment. Second, we do not have
robust information regarding known biologic determinants of MCL
such as Ki67, TP53 mutations or alterations, or blastic morphology,
as the central pathology review was not performed and biopsy was
not required at study entry. Third, the trial conduct of a CRM does
not allow for matching of the various arms by clinical characteristics;
therefore, there are differences in the arms. Thus, there is a risk that
arm B was identiﬁed as optimal based on clinical differences. However, the totality of the evidence in this study would suggest that
combination doses lower than the single-agent dose of both IBR
and VEN are safe and effective. Finally, our decision to limit the
combination to six 28-day cycles may, in retrospect, be too short of
a course. At the time of trial design, the intention was to use the
combination as a 6-month intensive therapy followed by maintenance therapy of the investigator's discretion (single-agent IBR was
recommended); therefore, survival (PFS and OS) are difﬁcult to
interpret. However, this study was not designed to evaluate the
long-term beneﬁt of this combination but rather to systematically
assess the optimal dose when both agents are used in
combination.
By starting treatment with VEN for all participants, we provide some
insight into the single-agent use of VEN in MCL. First, as has been
reported,30 an initial dose of 100 mg did cause TLS, even when limiting patients to low or medium tumor burden, and VEN must be
given with caution in MCL. While we did not test for response after
only 1 to 2 weeks of treatment with VEN alone, we anecdotally saw
rapid clinical improvements in disease burden for some patients
treated at the 100 mg daily dose. After the amendment, changing
the dosing strategy to start at 20 mg of VEN with a ramp-up to 50
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Time from cycle 1, day 1 (months)

Table 3. Cumulative toxicities by grade and arm

Total
n 5 35

Toxicity description
Grade

1

Hematologic

4

1

2

3

4

8

4

2

1

3

3
2

4
4

Diarrhea

14

4

1

2

3

1

1

1

2

2

1

3

3

1

1

1

1

7

3
2

1

1

4

2

Nausea

11

5

3

1

3

1

1

1

7

AST increase

4

1

2

6

ALT increase

2

1

1

2
1

Lung infection

4

1

2

2

1

1

1

1

Skin infection
3

1

Fatigue

5

4

Arthralgia/myalgia

5

1

Rash

6

1

2

1
1

1

1

1

1

2
2

1

1

1
1

2

2

1

Edema

4

1

1
10

3

1

Vomiting

Hypertension

3

1

2

1

Atrial ﬁb/ﬂutter

2

1
1

1

1
1

4

E
IBR 420
VEN 400
(n 5 5)

1

Dry mouth/dysgeusia

5

1

2

2

1
2
1

1

mg in 1 week and then to 100 mg over an additional week, we did
not see any additional TLS events or any signiﬁcant impact on
response rate at lower doses. Thus, a more rapid dose escalation
than is used in CLL26 can be used in MCL if monitoring carefully for
TLS and limiting patients to low to medium risk for TLS. It is often
important to reach an effective treatment dose with MCL as active
disease can be clinically signiﬁcant and require rapid treatment. A
dose-escalation starting at 20 mg and reaching a dose of 100 mg
by 1 week can allow for this if carefully monitored. By using VEN
before IBR, we were able to get to the maximum dose of both drugs
by 4 weeks, achieving an effective dose more quickly than the
OAsIs29 and AIM28 studies. This also avoided the concern for TLS
after peripheralization of leukemic MCL seen with IBR.
There was no major response advantage for higher doses of the
combination observed in this study. Given our dosing strategy,
we can only adequately discuss progressions occurring in the
ﬁrst 6 months of treatment. Nonresponse or progression following a response does not seem to be related to the dose of the
combination. This suggests underlying biology driving early resistance to the combination of IBR and VEN that we would hypothesize would not be adequately salvaged with higher doses of
either drug. Dosing of IBR has been reevaluated in the literature
recently37,38 and has been suggested that, at least in CLL, attenuated doses can still provide disease control. Mechanisms of
resistance with the combination have not been fully identiﬁed;
however, some investigators have identiﬁed potential targets. In
PORTELL et al

3

D
IBR 560
VEN 200
(n 5 4)

1

1
2

2

2

1

3

1

1

1

4

1

1

the AIM study, the SWI-SNF mutations seemed to mediate resistance through the upregulation of Bcl-xL.39 In preclinical models,
we have found that the tumor microenvironment modulation can
evoke IBR and VEN resistance through NF-kB-mediated upregulation of antiapoptotic proteins.40 With ongoing investigation, we
plan to utilize clinical specimens collected during this study to
evaluate these biologic determinants predicting response and
occurring at progression.
Finally, we elected to proceed with a dose-ﬁnding study at the
inception of this trial as both IBR and VEN were known to be
metabolized through CYP3A. Further, it was known that BTK occupancy was full and robust at the FDA-approved dose of 560 mg by
mouth daily, and even lower doses had full occupancy.15 Thus, the
2 drugs' interaction was hypothesized to increase effective drug levels that may allow for a lower dose without negative effects on efﬁcacy. Our ﬁnding of an optimal combination of IBR and VEN that is
lower than both drugs used as single agents would support this
hypothesis. Targeted small molecule inhibitors are increasingly being
combined in clinical practice, and it is important to recognize drug
interactions as doses used as a single agent may cause toxicities
when used in combination. Our study would suggest that IBR 420
mg by mouth daily and VEN 200 mg by mouth daily has a similar
response rate to other studies of the combination. At this dose,
there were fewer dose interruptions or reductions than previously
reported28,33,35 and improved toxicity proﬁle.
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Anemia
Abd pain/bloating

General

2

2
3

Thrombocytopenia

Upper respiratory

1496

1

C
IBR 280
VEN 400
(n 5 8)

3

Constipation

Infection

3

B
IBR 420
VEN 200
(n 5 16)

1

Neutropenia

Cardiac

2

Febrile neutropenia
Bleeding/bruising

Gastrointestinal

A
IBR 280
VEN 200
(n 5 2)
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